IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

Phase 2Enrolling By InvitationNCT06688175

The First Affiliated Hospital of Xiamen University32 enrolled

Overview

This prospective, multicenter, single-arm, open-label phase II clinical study aimed to investigate the efficacy and safety of intensity-modulated radiotherapy combined with lobaplatin-based concurrent chemotherapy in the treatment of elderly patients with nasopharyngeal carcinoma

Lobaplatin, as a third-generation platinum-based chemotherapeutic agent, demonstrates equivalent therapeutic efficacy to cisplatin but significantly lower toxicity. Preliminary clinical trials have confirmed that lobaplatin shows substantial effectiveness in treating various cancers including breast cancer, esophageal cancer, colorectal cancer, and cervical cancer. Importantly, lobaplatin does not exhibit cross-resistance with cisplatin or carboplatin, indicating a promising application prospect. Currently, lobaplatin has demonstrated clear efficacy in non-elderly nasopharyngeal carcinoma (NPC) chemotherapy. Guo Xiang et al. have confirmed that for non-elderly NPC patients, induction chemotherapy with lobaplatin followed by concurrent chemoradiotherapy may be a treatment option for locally advanced NPC. However, there is very limited research reporting on the use of lobaplatin in elderly NPC patients. Based on the above theoretical considerations and our research results, lobaplatin shows good safety and reliable efficacy in treating elderly NPC, with minimal gastrointestinal reactions and low incidence of renal, neurotoxic, and ototoxic effects. This approach significantly enhances the quality of life for locally advanced elderly NPC patients. Therefore, the efficacy and safety of lobaplatin in concurrent chemotherapy for elderly NPC deserve further investigation. This study aims to evaluate the recent efficacy, safety, and toxic side effects of lobaplatin combined with intensity-modulated radiotherapy in the treatment of elderly NPC. Designed as a multicenter, open-label, prospective study, it aims to verify whether lobaplatin is an effective concurrent chemotherapeutic agent for elderly NPC, while further improving the quality of life for these patients under guarantees of therapeutic efficacy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Neoplasms Elderly Chemotherapy

Interventions

IMRT combined with lobaplatin-based concurrent chemotherapyDRUG

IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy

Eligibility

Sex: ALLMin age: 65 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma; * Stage II-IVa (UICC 8th edition); * Acceptable induction chemotherapy and Tarceva targeted therapy; * No history of other malignant tumors; * Male or female, aged 65-80 years. * Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN; * Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN; * Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, and Hemoglobin ≥ 9 g/dL; * No severe dysfunction of vital organs such as heart and lung; * PS score ≤ 2 points Exclusion Criteria: * Distant metastases detected before treatment; * Refusal to sign the informed consent form; * Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons; * Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research); * Severe, uncontrolled infections or medical conditions; * Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy; * Laboratory tests: Total bilirubin \> Upper Limit of Normal (ULN); AST and/or ALT \> 1.5 times ULN with alkaline phosphatase \> 2.5 times ULN; * Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.; * Long-term use of immunosuppressants after organ transplantation; * Patients with a history of other malignant tumors before enrollment.

Locations (1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Outcomes

Primary Outcomes

objective response rate (ORR)

ORR encompasses both CR and PR.

Time frame: 6 months

Secondary Outcomes

Safety

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 3 months

Overall survival (OS)

OS was defined as the time of NPC diagnosis until death from any cause.

Time frame: 3 years

Locoregional relapse-free survival (LRFS)

LRFS was measured as the duration time from the diagnosis of nasopharyngeal carcinoma to the occurrence of relapse in the nasopharynx or neck lymph nodes or until the last follow-up.

Time frame: 3 years

Distant metastasis-free survival (DMFS)

DMFS was defined as the duration time of nasopharyngeal carcinoma diagnosis to the time of distant metastasis or the last follow-up.

Time frame: 3 years

Progression-free survival (PFS)

PFS was referred to as the time from nasopharyngeal carcinoma diagnosis to the date of disease progression.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.